Oncolytics Biotech Reports Positive Preclinical Data for Pelareorep in RAS-Mutated Cancers
ONCY has more than doubled off its 52-week low of $0.326 on elevated volume (2.7× avg).
Summary
Oncolytics Biotech announced initial positive preclinical data for its drug pelareorep in combination with RAS inhibitors, showing greater anti-tumor activity in solid tumor models.
Key Events · Product Development and Regulatory · ONCY
-
Positive Preclinical Data
Initial preclinical data shows pelareorep combined with RAS inhibitor modalities has greater anti-tumor activity in solid tumor models than individual approaches alone.
-
Expanded Study Plans
The company plans additional studies in pancreatic and colorectal cancer models to further evaluate immune activation, tumor response durability, and time-to-resistance.
-
Future Data Presentation
Full results from the initial preclinical studies are expected to be presented in the fall or winter of 2026.
Analysis · ONCY · Life Sciences
This filing announces initial positive preclinical data for pelareorep in combination with RAS inhibitor modalities, showing enhanced anti-tumor activity. This is important for Oncolytics Biotech as it expands the potential applications of its lead drug candidate, particularly in difficult-to-treat RAS-mutated pancreatic and colorectal cancers. The data supports further studies and could strengthen the company's pipeline and investor confidence, which is crucial given its recent 'going concern' warning and ongoing capital raises.
At the time of this filing, ONCY was trading at $1.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.1M. The 52-week trading range was $0.33 to $1.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.